Skinny Label and Induced Infringement: The Saga Continues
FDA Law Blog: Biosimilars
MAY 11, 2023
Koblitz — Well, we’re a little late to blogging about this, but the significance of the ongoing Teva v. GSK litigation to Hatch-Waxman aficionados makes this case still ripe for blogging. GSK skinny label case , the U.S. Six months after the Supreme Court asked the Solicitor General to submit a brief on behalf of the U.S.
Let's personalize your content